Table 1 Summary of dose-limiting toxicities

From: A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours

Cohort

Treatment

No. of subjects treated

No. of subjects with DLTs

1

GSK2256098 500 mg BID + trametinib 1.0 mg QD

3

2 – Grade 3 rash (pustular) - Grade 3 rash (dermatitis acneiform)

2

GSK2256098 500 mg BID + trametinib 0.5 mg QD

7

2 – Grade 3 decreased appetite - Grade 3 fatigue, Grade 3 rash (maculopapular)

3

GSK2256098 250 mg BID + trametinib 0.5 mg QD

10

1 – Grade 3 ejection fraction decreased

4

GSK2256098 500 mg BID + trametinib 0.25 mg QD

8

0

5

GSK2256098 500 mg BID + trametinib 0.375 mg QD

6

1 – Grade 2 dermatitis (acneiform)

  1. BID twice daily, DLT dose-limiting toxicity, PD pharmacodynamics, PK pharmacokinetics, QD once daily
Back to article page